Tandem Diabetes Care, Inc. (TNDM)
NASDAQ: TNDM · IEX Real-Time Price · USD
35.24
-0.32 (-0.90%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Tandem Diabetes Care Revenue
In the year 2023, Tandem Diabetes Care had annual revenue of $747.72M, a decrease of -6.68%. Revenue in the quarter ending December 31, 2023 was $196.80M, a -10.75% decrease year-over-year.
Revenue (ttm)
$747.72M
Revenue Growth
-6.68%
P/S Ratio
3.04
Revenue / Employee
$311,549
Employees
2,400
Market Cap
2.28B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 747.72M | -53.50M | -6.68% |
Dec 31, 2022 | 801.22M | 98.42M | 14.00% |
Dec 31, 2021 | 702.80M | 203.97M | 40.89% |
Dec 31, 2020 | 498.83M | 136.53M | 37.68% |
Dec 31, 2019 | 362.31M | 178.44M | 97.05% |
Dec 31, 2018 | 183.87M | 76.27M | 70.88% |
Dec 31, 2017 | 107.60M | 23.35M | 27.72% |
Dec 31, 2016 | 84.25M | 11.40M | 15.65% |
Dec 31, 2015 | 72.85M | 23.13M | 46.51% |
Dec 31, 2014 | 49.72M | 20.72M | 71.41% |
Dec 31, 2013 | 29.01M | 26.53M | 1,072.00% |
Dec 31, 2012 | 2.48M | - | - |
Dec 31, 2011 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teladoc Health | 2.60B |
ICU Medical | 2.26B |
Integra LifeSciences Holdings | 1.54B |
Guardant Health | 563.95M |
Inari Medical | 493.63M |
Corcept Therapeutics | 482.38M |
Denali Therapeutics | 330.53M |
STAAR Surgical Company | 322.42M |
TNDM News
- 18 days ago - Tandem Diabetes Care to Announce First Quarter 2024 Financial Results on May 2, 2024 - Business Wire
- 7 weeks ago - Tandem Diabetes Care Prices Upsized Private Placement of $275.0 Million of Convertible Senior Notes Due 2029 - Business Wire
- 7 weeks ago - Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes - Business Wire
- 2 months ago - Tandem Diabetes Care Announces Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance - Business Wire
- 2 months ago - Tandem Diabetes Care Launches Tandem Mobi, the World's Smallest, Durable Automated Insulin Delivery System - Business Wire
- 2 months ago - Tandem Diabetes Care Announces Upcoming Conference Presentations - Business Wire
- 3 months ago - Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024 - Business Wire
- 3 months ago - Tandem Diabetes Care's t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott's New FreeStyle Libre® 2 Plus Sensor - Business Wire